Display Settings:

Format

Send to:

Choose Destination
    Drug News Perspect. 2000 Jun;13(5):261-8.

    Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease.

    Source

    Motac Neuroscience Ltd., Incubator Building, Grafton St., Manchester, UK.

    Abstract

    Current symptomatic treatments for Parkinson's disease are based largely on dopamine replacement therapies; however, the fact that these treatments are characterized by many long-term side effects has led to widespread interest in nondopaminergic therapies. To date, a nondopaminergic therapy with comparable efficacy to dopamine replacement has not been devised. Here the authors discuss recent findings that systemic administration of a selective delta-opioid receptor agonist has powerful antiparkinsonian effects in rodent and primate models of Parkinson's disease that are equivalent to those of dopamine replacement. delta-Opioid receptor agonists may prove to be useful for the symptomatic treatment of Parkinson's disease in humans.

    PMID:
    12937640
    [PubMed]

      Supplemental Content

      Icon for Prous Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk